Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · Spain
Industry association · Belgium
Declared costs: €500K+ a year · in the register since 2011
Medicinal products for human use · Evaluation of the Regulation on serious cross-border threats to health
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Vaccines Europe (VE) · filed 27 Apr 2021 · source
Vaccines Europe (VE) believes that this evaluation is an opportunity to implement learnings from COVID-19 to ensure a future-proof and resilient healthcare system. The pandemic shows the importance of: EU crisis preparedness, a flexible regulatory environment, maintaining and enhancing innovative research and development, and an industrial capability and capacity in the EU.
Vaccines Europe (VE) · filed 4 Oct 2023 · source
Vaccines Europe (VE) concurs with the responses submitted by EFPIA, whilst raising implications and concerns regarding the proposed GPL revision for vaccines and the industry developing and manufacturing them. Although the vaccine industry is a relatively small part of the pharmaceutical industry, it is particularly important for the EU and its citizens as it delivers more value than any other innovative industry.
COFARES · filed 8 Nov 2023 · source
Positioning OF COFARES, S.L ANTE THE PROPOSALS FOR DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use and repealing Directive 2001/83/EC and Directive 2009/35/EC For the attention of the person concerned: Cofares, Sociedad Cooperativa Farmaceutica Española D.S.
Filed in Spanish · English published by the European Commission
COFARES · filed 12 Feb 2024 · source
In relation to the European Commission’s decision to assess the period of early application of the Regulation on serious cross-border threats to health, in accordance with its Article 33, COFARES, Spanish Pharmaceutical Cooperative (hereinafter ‘Cofares’), welcomes this initiative and has prepared this document with the aim of providing input and comments.
Filed in Spanish · English published by the European Commission
Vaccines Europe (VE) · filed 12 Feb 2024 · source
VE welcomes the opportunity to contribute to the evaluation of the Regulation 2022/2371. In our response, we focus on two points related to 1/Reporting on prevention preparedness and response planning and 2/Joint procurement of medical countermeasures.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.